Market Blog » The Arora Report Stock Market News

TAKE PROFITS ON AMERIGROUP $AGP RIGHT HERE AROUND $43

November 4, 2010

Our thesis is that with the Republicans controlling the house, in due course, Amerigroup will no longer enjoy lush payment from the government. In view of extremely bullish market conditions, it is prudent to exit the position here and short sell again when overall market is not so bullish. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return

TAKING PARTIAL PROFITS ON AMERIGROUP $AGP RIGHT HERE AT $42.72 AND MAINTAINING THE CORE SHORT POSITION

November 3, 2010

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

CONSIDER SELLING SHORT AMERIGROUP $AGP RIGHT HERE AROUND $43.25

November 3, 2010

WALL STREET DOES NOT APPRECIATE TRANSFORMATION OF CIENA $CIEN

November 3, 2010

Our analysis indicates acquisition of Nortel’s business is working out for CIEN. As investors realize the reality, large number of shorts will be squeezed possibly doubling the stock. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

WE HAVE BEEN PROVEN RIGHT ON AMPYRA FROM ACORDA THERAPEUTICS

November 1, 2010

Today Acorda Therapeutics (ACOR) reported earnings. Acorda stock has risen on hopes for blockbuster sales of its MS walking drug Ampyra. First the stock went higher, but started falling when investors realized that sales will drop next quarter. Our negative stance on Ampyra sales has proven right. Earlier in the year, when Wall Street was unanimously wildly bullish on Acorda, we wrote the following: In the short term, the bulls may be right. For the first time, MS patients with difficulty in walking have hope. MS patients, in general tend to be very knowledgeable about new drugs and as such they

NEW RARE EARTH METALS ETF $REMX SENDS MOLYCORP $MCP AND RARE EARTH ELEMENTS $REE INTO RAREFIED TERRITORY

October 27, 2010

In anticipation of tomorrow’s launch of a Rare Earth ETF by Van Eck under the ticker symbol “REMX” Molycorp and Rare Earth Elements have strongly moved up. We will continue to take advantage of this up move by trading these two stocks in a manner described in the prior post to take advantage of intraday volatility. If the stocks go much higher, we will continue to scale in our core short positions. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since